Gavin and I try to peel apart the layers of the LeoPARDS Trial which assesses the benefits of levosimendan for the prevention of organ dysfunction in sepsis. It's another interesting study which actually asks more questions that it answers, but all questions we may try to answer one day with more research.
I am still hoping to get together with Danni Bear the dietician in the near future to talk about the latest findings from ASPEN. Watch this space.
Neuro ICU Transfusion Thresholds: HEMOTION vs TRAIN and the Case for a 90 g/L TargetI review why the standard restrictive ICU transfusion trigger of 70 g/L may fail in acute brain injury, where autoregulation is impaired, intracranial pressure is elevated, and vulnerable penumbral tissue is prone to hypoxia. I walk through two major RCTs: HEMOTION (742
Read More
Tom, one of my colleagues from the Critical Care Outreach Team and I discuss this paper and its findings reaching our own conclusions. Deferring Arterial Catheterisation in Patients with Septic Shock.
Read More
We return to our 48-year-old patient: jaundiced, hypotensive, drowsy, and bleeding. In decompensated cirrhosis, every treatment targets a disrupted system — splanchnic vasodilation, portal hypertension, toxin accumulation, and renal hypoperfusion.Although these patients look fluid overloaded, they are effectively hypovolaemic. Start with small aliquots of balanced crystalloid, avoiding 0.9% saline. In hepatorenal syndrome or tense ascites, 20% albumin is
Read More